NanoViricides, Inc. Reports It has Successfully Improved HIVCide Drug Candidate in Cell Culture Studies

Published: Sep 16, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB:NNVCD) (the "Company") reports that it has successfully improved upon its previous lead anti-HIV drug candidate, based on cell culture studies. An improved broad-spectrum anti-HIV nanoviricide that inhibited two distinctly different types of HIV-1 viruses equally well has been identified. This drug candidate also exhibited a very large therapeutic index. The Company has previously reported that it is optimizing the anti-HIV drug candidate. These cell culture studies were conducted by Southern Research Institute, Frederick, MD.

Help employers find you! Check out all the jobs and post your resume.

Back to news